IL139197D0 - Use of corticotropin releasing factor antagonists and related compositions - Google Patents

Use of corticotropin releasing factor antagonists and related compositions

Info

Publication number
IL139197D0
IL139197D0 IL13919700A IL13919700A IL139197D0 IL 139197 D0 IL139197 D0 IL 139197D0 IL 13919700 A IL13919700 A IL 13919700A IL 13919700 A IL13919700 A IL 13919700A IL 139197 D0 IL139197 D0 IL 139197D0
Authority
IL
Israel
Prior art keywords
use
releasing factor
corticotropin releasing
related compositions
factor antagonists
Prior art date
Application number
IL13919700A
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16234099P priority Critical
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL139197D0 publication Critical patent/IL139197D0/en

Links

IL13919700A 1999-10-29 2000-10-23 Use of corticotropin releasing factor antagonists and related compositions IL139197D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16234099P true 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
IL139197D0 true IL139197D0 (en) 2001-11-25

Family

ID=22585210

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13919700A IL139197D0 (en) 1999-10-29 2000-10-23 Use of corticotropin releasing factor antagonists and related compositions

Country Status (11)

Country Link
US (2) US6589947B1 (en)
EP (1) EP1097709A3 (en)
KR (1) KR20010051274A (en)
AU (1) AU776724B2 (en)
CA (1) CA2325069A1 (en)
CO (1) CO5271670A1 (en)
HU (1) HU0004194A3 (en)
IL (1) IL139197D0 (en)
NZ (1) NZ507825A (en)
PE (1) PE08072001A1 (en)
ZA (1) ZA200006008B (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1449532A1 (en) * 1999-08-27 2004-08-25 Pfizer Products Inc. Compound [2-(4-chloro-2,6-dimethyl-phenoxy)- 3,6-dimethyl-pyridin-4-yl]- (1-ethyl-propyl)- amine and use as CRF antagonist
IL148905D0 (en) * 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
CO5271670A1 (en) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonists corticitropina releasing factor and related compositions
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
AU2002253357B2 (en) * 2001-04-30 2006-08-24 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
AU2003215379A1 (en) * 2002-02-22 2003-09-09 Pharmacia And Upjohn Company Substituted pyrimidinones and pyrimidinthiones
BR0308391A (en) * 2002-03-13 2005-01-11 Pharmacia & Upjohn Co Llc Derivatives of pyrazolo (1,5-a) pyridine as modulators of neurotransmitter
PL373043A1 (en) * 2002-03-26 2005-08-08 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003223475A1 (en) 2002-04-26 2003-11-10 Pharmacia And Upjohn Company Substituted pyrazine derivatives
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
BR0312575A (en) * 2002-07-08 2005-05-03 Pfizer Prod Inc Modulators of glucocorticoid receptor
US20040116444A1 (en) * 2002-09-12 2004-06-17 Corbett Jeffrey W. Substituted 1,4-pyrazine derivatives
AR041470A1 (en) 2002-10-17 2005-05-18 Upjohn Co Pyrrolo (1,2 - b) pyridazine and its uses
US8450379B2 (en) * 2002-11-05 2013-05-28 Corcept Therapeutics, Inc. Methods for treating migraine
US20060052354A1 (en) * 2002-11-05 2006-03-09 Corcept Therapeutics, Inc. Methods for treating migraine
BR0315845A (en) * 2002-11-21 2005-09-27 Pharmacia & Upjohn Co Llc pyrazine compounds as modulators of CRF
DE602004009295T2 (en) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism for the prevention and treatment of metabolic-related diseases such as diabetes or hyperglycemia
JP2006524223A (en) * 2003-04-23 2006-10-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Substituted pyrimidinone and pyrimidine thione as Crf antagonists
BRPI0410097A (en) * 2003-05-07 2006-05-16 Pharmacia & Upjohn Co Llc Compounds pyrrol [1,2-b] pyridazine
JP2006525993A (en) 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Crf1 a receptor antagonist compound
CA2524352A1 (en) 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Substituted pyrimidine derivatives
EP1626965A1 (en) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Company LLC Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders
EP2292620A3 (en) * 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto
CA2535120A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
MY145983A (en) 2003-08-27 2012-05-31 3M Innovative Properties Co Aryloxy and arylalkyleneoxy substituted imidazoquinolines
CA2537763A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
UY28526A1 (en) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Glucocorticoid mimetics, methods of preparing pharmaceutical compositions and uses thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AR046046A1 (en) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolines substituted alkoxy. pharmaceutical compositions.
AU2004291122A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CN1906193A (en) 2003-11-14 2007-01-31 3M创新有限公司 Oxime substituted imidazo ring compounds
KR101130928B1 (en) 2003-11-25 2012-04-12 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Substituted imidazo ring systems and methods
US20070293511A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Squibb Bristol Myers Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
WO2006083440A2 (en) 2004-12-30 2006-08-10 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
JP5543068B2 (en) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー Chiral fused [1,2] imidazo [4,5-c] cyclic compound
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
WO2006107853A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006239929B2 (en) 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7815905B2 (en) 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
AU2007214411B2 (en) * 2006-02-15 2010-07-01 Abbott Laboratories Pyrazoloquinolones are potent PARP inhibitors
EP1834641A1 (en) * 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
CA2671990A1 (en) * 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN102112476A (en) * 2008-06-06 2011-06-29 贝林格尔.英格海姆国际有限公司 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP3031324A3 (en) 2008-06-10 2016-09-07 AbbVie Inc. Tricyclic kinase inhibitors
KR101774035B1 (en) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. IMIDAZO[l,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE1O INHIBITORS
WO2011068899A1 (en) 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
CR20170159A (en) 2009-12-01 2017-06-26 Abbvie Inc New tricyclic compounds
US8329705B2 (en) 2009-12-30 2012-12-11 Arqule, Inc. Substituted triazolo-pyrazine compounds
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Imidazo (1,2-a) pyrazine and their use as inhibitors of PDE10
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
JP6174695B2 (en) 2012-07-09 2017-08-02 ヤンセン ファーマシューティカ エヌ.ベー. Inhibitor of phosphodiesterase 10 enzyme
TW201422590A (en) 2012-09-07 2014-06-16 Abbvie Inc Heterocyclic nuclear hormone receptor modulators
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc Heterocyclic nuclear hormone receptor modulators
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
CA3002220A1 (en) 2015-10-16 2017-04-20 Abbvie Inc. Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US4871739A (en) * 1987-01-21 1989-10-03 Merck & Co., Inc. Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
EP0324520A3 (en) * 1988-01-14 1990-08-16 Merck & Co., Inc. Alkyl-piperazinyl-5-6-alkylenepyrimidines
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
EP0674641B1 (en) 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
US5347973A (en) * 1993-06-25 1994-09-20 Walker Design Inc. Vacuum relief valve
CN1142817A (en) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
DK0765327T3 (en) * 1994-06-16 1999-11-29 Pfizer Pyrazolo- and pyrrolopyridines
FR2735777B1 (en) 1995-06-21 1997-09-12 Sanofi Sa Derivatives of 4-phenylaminothiazole, their process for the preparation and pharmaceutical compositions containing them
US5955613A (en) * 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
AT243697T (en) * 1995-12-08 2003-07-15 Pfizer Substitutierte heterozyclische derivatives as antagonists crf
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
DE880523T1 (en) 1996-02-07 2002-07-04 Janssen Pharmaceutica Nv Pyrazolopyrimidine as crf receptor antagonists
ES2167710T3 (en) * 1996-02-07 2002-05-16 Janssen Pharmaceutica Nv Tiofenopirimidinas.
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
SK14099A3 (en) * 1996-08-06 2000-05-16 Pfizer Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
KR20000035934A (en) 1996-08-28 2000-06-26 디. 제이. 우드, 스피겔 알렌 제이 Substituted 6,5-hetero-bicyclic derivatives
FR2754258B1 (en) * 1996-10-08 1998-12-31 Sanofi Sa Derivatives aminothiazole, their process for the preparation and pharmaceutical compositions containing them
DK0977737T3 (en) * 1997-04-22 2004-01-26 Janssen Pharmaceutica Nv CRF antagonistic quinoline and quinazoline
DK0901786T3 (en) * 1997-08-11 2007-10-08 Pfizer Prod Inc Solid pharmaceutical dispersions possess increased bioavailability
WO1999017761A1 (en) 1997-10-06 1999-04-15 Shaman Pharmaceuticals, Inc. Use of nordihydroguaiaretic acid to lower serum triglycerides, blood pressure and to treat syndrome x
GB9802251D0 (en) * 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
AU3464599A (en) * 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted 9h-pyridino(2,3-b)indole and 9h-pyrimidino(4,5-b)indole derivatives
JP2002510695A (en) * 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー Corticotropin releasing factor (CRF) thiazolo as antagonists [4,5-d] pyrimidine and pyridine
CO5271670A1 (en) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonists corticitropina releasing factor and related compositions

Also Published As

Publication number Publication date
EP1097709A3 (en) 2005-12-21
US6777404B2 (en) 2004-08-17
CA2325069A1 (en) 2001-04-29
NZ507825A (en) 2004-11-26
KR20010051274A (en) 2001-06-25
AU776724B2 (en) 2004-09-16
ZA200006008B (en) 2002-04-26
HU0004194A3 (en) 2002-03-28
HU0004194D0 (en) 2001-01-29
HU0004194A2 (en) 2001-12-28
US6589947B1 (en) 2003-07-08
AU6669500A (en) 2001-05-03
EP1097709A2 (en) 2001-05-09
PE08072001A1 (en) 2001-08-03
US20030199527A1 (en) 2003-10-23
CO5271670A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
TWI304324B (en) Pestcide composition and uses thereof
TWI298064B (en) 2-amimopyridine and the medical use of the same
SI1132463T1 (en) Cosmetic composition comprising an antagonist of the neuropeptide Y receptor
HRP20010524A2 (en) Benzoheterocycles and their use as mek inhibitors
HK1027979A1 (en) Indole derivatives and their use as mcp-1 antagonists
HU0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
HU0101275A3 (en) Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
SI1329456T1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
IL187907D0 (en) Analogues of glp-1 and uses thereof
IL155712D0 (en) Aminothiazoles and their use as adenosine receptor antagonists
HU0303108A3 (en) Substituted pyrazoles and pharmaceutical compositions containing them
ZA200002767B (en) Topical zinc compositions and methods of use.
AU8729101A (en) Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
EP1177168A4 (en) Caspase inhibitors and the use thereof
IN215218B (en) Substituted dihydro 3-halo-1H-pyrazole-5-carboxylates their preparation and use
IL180523D0 (en) Compositions for iapp-inhibition and uses thereon
IL148384A (en) Glucopyranosyloxypyrazole derivatives and medicinal compositions containing the same
HU0101999A3 (en) 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
IL162000D0 (en) Injectable depot compositions and use thereof
SI1296959T1 (en) Methods and compositions utilizing quinazolinones
IL128792A (en) Heterocyclic ketones and pharmaceutical compositions comprising same
HU0400384A3 (en) Benzamidine derivative and pharmaceutical compositions containing them and their use
GB0001752D0 (en) Particulate compositions and their manufacture
IL144294D0 (en) P53 inhibitors and therapeutic use of the same
IL156843D0 (en) Combined use of factor vii polypeptides and factor viii polypeptides